Clinical Trial Regulations in India: New Drugs and Clinical Trials Rules 2019 Framework

Executive Summary

Clinical trials are the cornerstone of pharmaceutical innovation, serving as the critical bridge between laboratory discovery and patient access to new therapies. India's clinical trial landscape has undergone transformative regulatory evolution, culminating in the New Drugs and Clinical Trials Rules, 2019 (NDCT Rules 2019), which replaced the outdated 2005 framework. This comprehensive regulatory overhaul emphasizes patient safety, ethical conduct, compensation for trial-related injuries, and alignment with global harmonization standards.

Key Statistics (2024-25):

• Active clinical trial registrations in India: 2,847
• CTRI (Clinical Trials Registry India) registrations: 32,000+ cumulative
• Ethics Committee approvals processed annually: 4,500+
• Serious Adverse Event (SAE) reports: 1,200-1,500 annually
• Compensation claims for trial-related injuries: ₹45-60 crores awarded (2023-24)
• CDSCO approvals for new drug clinical trials: 280-320 annually
• Average clinical trial approval time: 90-120 days (post-2019 reforms)
• India's global share of clinical trials: 2.8% (growing from 1.5% in 2015)

This legal blog provides an exhaustive analysis of the NDCT Rules 2019 framework, Ethics Committee requirements, informed consent protocols, compensation mechanisms for trial-related injuries, global harmonization standards, judicial precedents, and compliance best practices for pharmaceutical sponsors, investigators, and institutional stakeholders.

Table of Contents

1. Legislative Framework and Regulatory Evolution
2. New Drugs and Clinical Trials Rules 2019: Key Provisions
3. Ethics Committee Requirements and Composition
4. Informed Consent: Legal and Ethical Standards
5. Compensation for Trial-Related Injuries and Deaths
6. Serious Adverse Event Reporting and Pharmacovigilance
7. Global Harmonization: ICH-GCP and Regulatory Alignment
8. Judicial Precedents and Case Law Analysis

1. Legislative Framework and Regulatory Evolution

1.1 Statutory Basis

Clinical trials in India are governed by:

• Drugs and Cosmetics Act, 1940 (Section 12, 33)
• Drugs and Cosmetics Rules, 1945 (Schedule Y)
• New Drugs and Clinical Trials Rules, 2019 (superseding 2005 Rules)
• Medical Devices Rules, 2017 (for device clinical investigations)
• Indian Medical Council (Professional Conduct, Etiquette and Ethics) Regulations, 2002

Constitutional Framework:

1.2 Historical Evolution: From 2005 to 2019

2005 Clinical Trial Rules (Schedule Y, Appendix XII): Problems identified:

• Lengthy approval timelines (180-240 days)
• Ambiguous compensation provisions
• Insufficient ethical oversight mechanisms
• Limited patient protection safeguards
• Non-alignment with ICH-GCP standards

Regulatory Crisis (2010-2013):

• Supreme Court intervention in Swasthya Adhikar Manch v. Ministry of Health (2013)
• Imposition of moratorium on new trial approvals (2013-2014)
• Demand for stronger patient protection and compensation

2019 Reforms - Key Improvements:

1.3 Regulatory Authorities and Jurisdiction

Central Licensing Authority (DCGI):

• Approval of new drug clinical trials (Phase I, II, III, IV)
• Approval of bioavailability/bioequivalence (BA/BE) studies
• Registration and oversight of Ethics Committees
• Regulatory inspections and compliance audits
• Serious Adverse Event (SAE) adjudication

Ethics Committees (ECs):

• Protocol review and approval
• Informed consent verification
• Monitoring of trial conduct
• SAE review and causality assessment
• Protection of trial participant rights

Institutional Review Boards (IRBs): Hospitals, research institutions, and contract research organizations (CROs) establish IRBs as Ethics Committees for institutional trial oversight.

2. New Drugs and Clinical Trials Rules 2019: Key Provisions

2.1 Definition of "New Drug" (Rule 2(w))

A drug is considered "new" if:

Example: In Deepak Khosla v. Union of India (2019), the Delhi High Court held that embryonic stem-cell therapy falls under "new drugs" and requires regulatory approval under Rule 2(1)(w).

2.2 Clinical Trial Phases and Approval Process

Phase Classification:

Approval Timeline (Rule 7):

1. Submission: Sponsor submits Form CT-04 to DCGI with protocol, investigator's brochure, Ethics Committee approval
2. CDSCO Review: Technical evaluation of scientific design, safety, ethics compliance
3. Deemed Approval: If DCGO does not respond within 90 days, trial deemed approved (major reform)
4. Queries/Clarifications: DCGI may request additional information within 30 days
5. Final Approval: CT-05 approval letter issued, trial may commence

2.3 Exemptions and Fast-Track Pathways

Waiver of Phase I/II in India (Rule 10):

Compassionate Use / Expanded Access (Rule 11):

• For serious/life-threatening conditions with no treatment alternative
• Emergency use outside clinical trial framework
• Requires Ethics Committee and DCGI approval
• Informed consent mandatory

3. Ethics Committee Requirements and Composition

3.1 Registration and Functioning (Rule 8)

Mandatory Registration with CDSCO: All Ethics Committees conducting clinical trial review must:

• Register with CDSCO on Form CT-06
• Renew registration every 3 years
• Maintain Standard Operating Procedures (SOPs)
• Undergo periodic CDSCO audits

Ethics Committee Composition (Schedule VI):

Total Members: Minimum 7; Maximum 15

Quorum Requirements:

• At least 50% members present
• At least 1 independent member and 1 layperson
• Chairperson or designated alternate present

3.2 Functions and Responsibilities

Pre-Trial Responsibilities:

During-Trial Oversight:

Conflict of Interest Management:

• Members with financial interest in sponsor must recuse
• Investigators cannot participate in EC deliberations on their own trials
• Institutional officials with administrative authority should not be Chairperson

4. Informed Consent: Legal and Ethical Standards

4.1 Informed Consent Requirements (Rule 9)

Essential Elements of Informed Consent (Schedule VI, Part A):

1. Study Information:

   • Purpose and objectives of the trial
   • Trial design and procedures
   • Expected duration of participation

2. Risk Disclosure:

   • All foreseeable risks and discomforts
   • Potential adverse effects
   • Alternative treatments available

3. Benefits and Compensation:

   • Expected benefits to participant and society
   • Compensation for trial-related injuries
   • No payment for participation (except reasonable expenses)

4. Rights of Participants:

   • Voluntary participation
   • Right to withdraw at any time without penalty
   • Confidentiality and data protection

5. Contact Information:

   • Investigator details
   • Ethics Committee contact
   • Emergency contact 24/7

Language and Comprehension:

• Informed consent form (ICF) in local language/vernacular
• Simple, non-technical language (8th-grade reading level)
• No coercive or exculpatory language
• Explained by qualified investigator, not subordinate staff

4.2 Audio-Video Recording of Consent (Rule 9A)

Mandatory for Vulnerable Populations:

Recording Protocol:

• Clear video showing participant, investigator, witness
• Audio capturing entire consent explanation and participant's questions
• Participant's voluntary agreement recorded
• Recording stored securely for duration of trial + 3 years
• Submitted to CDSCO on request

Impartial Witness Requirement:

• Individual independent of trial team
• Literate, not related to participant or investigator
• Attests that consent process was fair and voluntary
• Signs consent form as witness

4.3 Consent for Vulnerable Populations

Pediatric Trials (Children <18 years):

• Parent/legal guardian consent mandatory
• Child's assent required if >12 years
• No greater than minimal risk unless direct therapeutic benefit
• Ethics Committee must include pediatrician

Pregnant/Lactating Women:

• Consent from woman and spouse (where applicable)
• Risk assessment for fetus/infant mandatory
• Preclinical reproductive toxicology data required

Mentally Incapacitated Persons:

• Consent from legally authorized representative (LAR)
• Trial must offer potential direct benefit
• Assent from participant if capable of understanding
• Enhanced EC oversight and monitoring

Emergency Situations (Deferred Consent):

• If immediate intervention necessary to save life
• Informed consent impractical due to medical urgency
• Consent obtained from LAR as soon as possible
• Ethics Committee prior approval of deferred consent protocol

5. Compensation for Trial-Related Injuries and Deaths

5.1 Compensation Framework (Rule 12)

Mandatory Insurance Coverage: All clinical trial sponsors must:

• Obtain insurance coverage for trial participants
• Insurance amount calculated based on formula in Schedule VI, Part C
• Insurance policy covers trial-related injuries and deaths
• No cap on compensation amount
• Participant does not bear cost of treatment for trial-related injury

Compensation Eligibility:

5.2 Compensation Calculation Formula (Schedule VI, Part C)

Formula:

Compensation = Base Amount × Multiplier Factor × Causality Percentage

Where:

• Base Amount: ₹8,00,000 (revised periodically by CDSCO)
• Multiplier Factor: Based on age, occupation, dependency ratio
• Causality Percentage: Determined by Ethics Committee (0-100%)

Age-Based Multiplier:

Example Calculation:

Participant: 35-year-old male, earning ₹30,000/month Event: Permanent 50% disability with 80% causality established

• Base Amount: ₹8,00,000
• Multiplier: 16 (age 35)
• Causality: 80%
• Disability: 50%

Compensation = ₹8,00,000 × 16 × 0.80 × 0.50 = ₹51,20,000

Plus: Medical expenses, rehabilitation costs, pain & suffering (additional)

5.3 Causality Assessment and Adjudication

Ethics Committee Causality Determination:

Appeal Process:

• Participant may appeal EC causality decision to DCGI
• Independent expert committee reviews case
• Final decision by DCGI binding (subject to judicial review)

6. Serious Adverse Event Reporting and Pharmacovigilance

6.1 Definitions and Classification

Adverse Event (AE): Any untoward medical occurrence in a trial participant, whether or not related to the investigational product.

Serious Adverse Event (SAE): An adverse event that:

• Results in death
• Is life-threatening
• Requires hospitalization or prolongation of existing hospitalization
• Results in persistent or significant disability/incapacity
• Is a congenital anomaly/birth defect
• Is a medically important event

Suspected Unexpected Serious Adverse Reaction (SUSAR): SAE that is both suspected to be related to the investigational product AND unexpected (not listed in investigator's brochure).

6.2 Reporting Timelines (Rule 14)

To Ethics Committee:

To DCGI:

Global SAE Reporting: For multi-country trials, sponsor must report all global SUSARs occurring in any country to Indian EC and DCGI within same timelines.

6.3 Pharmacovigilance Program for India (PvPI)

Integration with Clinical Trials:

• All trial sites must report ADRs to PvPI database
• Investigators trained in ADR reporting via VigiFlow
• Trial data contributes to national drug safety surveillance
• Signals detected in trials trigger regulatory review

7. Global Harmonization: ICH-GCP and Regulatory Alignment

7.1 International Council for Harmonisation - Good Clinical Practice (ICH-GCP)

Adoption in India: The New Drugs and Clinical Trials Rules 2019 align substantially with ICH-GCP E6(R2) guidelines.

7.2 Recognition of Foreign Clinical Trial Data

Mutual Recognition:

• India recognizes Phase I/II data from USFDA/EMA/PMDA approved trials
• Indian PK studies may be waived if population similarity demonstrated
• Global multi-center trials may include Indian sites with single DCGI approval

Bridging Studies: If ethnicity or environmental factors may affect drug response:

• PK/PD bridging study in Indian population required
• Typically 50-100 participants
• Compares Indian data to reference population
• Required for biologics, immunomodulators, narrow therapeutic index drugs

8. Judicial Precedents and Case Law Analysis

8.1 Deepak Khosla v. Union of India (2019)

Citation: W.P.(C) CM Appl 26423-24/2019, Delhi High Court, Decided on 28-05-2019 Bench: Justice G.S. Sistani, Justice Jyoti Singh

Facts: Deepak Khosla, suffering from glaucoma with macular degeneration, had been receiving embryonic stem-cell therapy at Nutech Mediworld clinic since July 2016. Following notification of the New Drugs and Clinical Trials Rules, 2019, which classified stem-cell derived products as "new drugs" under Rule 2(1)(w), the clinic ceased treatment, citing the need for regulatory approval.

Petitioner's Contentions:

• Discontinuation of treatment would severely harm his health
• Requested interim direction to allow clinic to continue treatment until regulatory license obtained
• Argued that abrupt cessation violated his right to health under Article 21

Respondent's Contentions:

• Respondents (Union of India and others) accepted notice to show cause
• Did not oppose interim relief
• Maintained that stem-cell therapy requires regulatory compliance under 2019 Rules

Core Legal Issue: Whether embryonic stem-cell therapy falls within the definition of "new drugs" under Rule 2(1)(w) of the New Drugs and Clinical Trials Rules 2019, thereby requiring CDSCO licensing?

Court's Analysis:

The Delhi High Court examined:

1. Definition of "New Drug" (Rule 2(1)(w)): The 2019 Rules explicitly include stem-cell derived products in the definition of "new drugs," thereby bringing them under CDSCO regulatory purview.

2. Regulatory Necessity: The Court recognized that stem-cell therapies involve significant safety and efficacy uncertainties, justifying regulatory oversight.

3. Patient Welfare vs. Regulatory Compliance: Balancing the petitioner's urgent medical need with the statutory requirement for licensing, the Court adopted a pragmatic approach.

Judgment:

The Court granted interim relief with the following directions:

1. Continuation of Treatment: Nutech Mediworld clinic directed to continue providing embryonic stem-cell therapy to Deepak Khosla pending regulatory clearance.

2. Information Submission: Clinic must submit all requisite information to CDSCO within one week, including:

   • Details of stem-cell therapy protocol
   • Safety and efficacy data
   • Number of patients treated
   • Adverse event reports

3. CDSCO Determination: CDSCO directed to examine whether the therapy falls under "new drugs" and communicate its view expeditiously.

4. Regulatory Pathway: Clinic must apply for appropriate license/approval as per 2019 Rules.

Legal Significance:

1. Clarification of "New Drug" Scope: Stem-cell derived products definitively classified as "new drugs," requiring clinical trial approval before commercialization.

2. Balancing Patient Rights and Regulation: Court may grant interim relief for continued access to experimental therapies while regulatory approval is pursued, recognizing Article 21 right to health.

3. Regulatory Transition Period: Therapies offered prior to 2019 Rules may continue under interim arrangements subject to information submission and CDSCO review.

4. Precedent for Investigational Therapies: Establishes framework for compassionate use/expanded access pending formal approval.

Practical Implications:

Follow-Up: Post-2019 judgment, CDSCO issued guidelines for stem-cell therapy clinical trials, mandating:

• Ethics Committee approval
• Informed consent with disclosure of investigational status
• Adverse event reporting
• No commercialization until full approval

8.2 Supreme Court Intervention: Swasthya Adhikar Manch v. Ministry of Health (2013)

Citation: Writ Petition (Civil) No. 33 of 2012, Supreme Court of India Impact: Landmark PIL that transformed Indian clinical trial regulation

Background (2010-2013 Crisis):

• Several clinical trial-related deaths reported (2,800+ deaths during 2005-2012)
• Inadequate compensation for trial participants
• Lack of informed consent safeguards
• Weak Ethics Committee oversight

Supreme Court Directions (2013):

1. Moratorium on New Trials: Temporary suspension of new clinical trial approvals until regulatory reforms implemented

2. Compensation Mandate:

   • Formula-based compensation for trial-related injuries and deaths
   • No discretion to deny compensation if causality established
   • Insurance coverage mandatory

3. Audio-Video Consent: Mandated audio-video recording of informed consent for vulnerable populations

4. Ethics Committee Reforms:

   • Registration with CDSCO
   • Independent members and layperson representation
   • Conflict of interest disclosure

5. Adverse Event Reporting: Stricter timelines and accountability

Regulatory Response: These Supreme Court directions were incorporated into the New Drugs and Clinical Trials Rules 2019, transforming the legal landscape and restoring India's credibility in global clinical research.

Long-Term Impact:

• India's clinical trials increased from 1,500 (2013) to 2,847 (2024)
• Compensation claims processed transparently
• Ethics Committee quality improved significantly
• International sponsors regained confidence

Compliance Checklist for Clinical Trial Sponsors

Pre-Trial Phase

• Protocol approved by registered Ethics Committee (EC)
• Form CT-04 submitted to DCGI with all annexures
• Investigator's Brochure (IB) updated and provided to EC/investigators
• Informed Consent Forms in local language reviewed and approved by EC
• Insurance policy obtained covering all trial participants
• Compensation formula calculated and disclosed in ICF
• Audio-video consent recording equipment arranged (for vulnerable populations)
• Site selection and investigator qualification verification completed
• Training of investigators and site staff on protocol, GCP, SAE reporting
• Trial registration on CTRI (Clinical Trials Registry India) completed

During Trial Phase

• SAEs reported to EC within 24 hours (fatal/life-threatening) or 7 days (other)
• SUSARs reported to DCGI within 7/14 days as per Rule 14
• Protocol amendments submitted to EC before implementation
• Informed consent obtained and audio-video recorded (where required) before each participant enrollment
• Source documents maintained contemporaneously
• Sponsor monitoring visits conducted as per monitoring plan
• Annual safety reports submitted to DCGI within 60 days of data lock
• EC continuing review completed annually
• Adverse event database updated in real-time
• Participant safety monitored via Data Safety Monitoring Board (for Phase III trials)

Post-Trial Phase

• Trial closure notification submitted to EC and DCGI within 30 days
• Final study report submitted to DCGI within 12 months of trial completion
• All SAEs followed up to resolution or stable state
• Compensation claims processed within 90 days of causality determination
• Trial results submitted to CTRI within 12 months
• Essential documents archived for 3 years post-trial completion
• Participant medical records transferred to treating physician (with consent)

Conclusion

The New Drugs and Clinical Trials Rules 2019 represent a paradigm shift in India's clinical trial regulatory framework, prioritizing patient safety, ethical conduct, and transparency while fostering pharmaceutical innovation. The comprehensive reforms—including mandatory compensation, audio-video consent for vulnerable populations, 90-day deemed approval, and alignment with ICH-GCP standards—have restored global confidence in India's clinical research ecosystem.

Key Takeaways for Stakeholders:

1. Patient Protection Paramount: Compensation for trial-related injuries is now mandatory and formula-based, eliminating discretionary denial.

2. Ethics Committee Centrality: Registered ECs with independent oversight are the cornerstone of ethical clinical trials.

3. Informed Consent Excellence: Audio-video recording for vulnerable populations ensures voluntariness and comprehension.

4. Fast-Track Approvals: 90-day deemed approval and recognition of foreign data reduce regulatory timelines significantly.

5. Judicial Oversight: Courts (as seen in Deepak Khosla) balance patient rights with regulatory compliance, enabling compassionate access.

6. Global Harmonization: Adoption of ICH-GCP standards positions India as a credible destination for global multi-center trials.

The judicial precedents analyzed—particularly the Supreme Court's transformative intervention in Swasthya Adhikar Manch and the Delhi High Court's pragmatic approach in Deepak Khosla—demonstrate that India's legal system actively safeguards trial participants while fostering innovation. Pharmaceutical sponsors, investigators, and institutional stakeholders must embrace this robust regulatory framework to conduct ethical, scientifically rigorous, and legally compliant clinical trials that benefit patients and advance medical science.